Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDS 0103

Next Previous
Search
Drug Profile

PDS 0103

Alternative Names: PDS-0103; Versamune®-MUC1

Latest Information Update: 08 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDS Biotechnology Corporation
  • Developer National Cancer Institute (USA); PDS Biotechnology Corporation
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 13 Mar 2025 Preclinical development in Breast-cancer is ongoing in USA (SC, Injection) (PDS Biotechnology Corporation website; March 2025)
  • 13 Mar 2025 Preclinical development in Colorectal-cancer is ongoing in USA (SC, Injection) (PDS Biotechnology Corporation website; March 2025)
  • 13 Mar 2025 Preclinical development in Non-small-cell-lung-cancer is ongoing in USA (SC, Injection) (PDS Biotechnology Corporation website; March 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top